Cannabis Bets On Hemp; Mike Tyson On Rescheduling

This week’s Trade to Black podcast focused on developments in federal cannabis rescheduling, the strategic role of cultural figures like Mike Tyson, and the rapid evolution of the hemp beverage market.

Michael Bronstein of the American Trade Association for Cannabis and Hemp joined the show to discuss the growing political relevance of cannabis reform, particularly in the context of celebrity advocacy. Tyson’s viral criticism of cannabis being listed as a Schedule I drug, while fentanyl remains Schedule II, reignited conversations about drug scheduling policy. Bronstein explained that although Tyson’s comparison is technically imperfect—since many fentanyl analogues are Schedule I—his visibility and influence, especially with former President Donald Trump, are politically significant to the rescheduling effort.

Bronstein emphasized that Trump’s past use of pop culture to shape policy may again play a role if cannabis reform becomes politically profitable. The discussion also highlighted potential avenues for aligning cannabis reform with Trump’s political agenda, particularly through national security narratives such as the role of illicit Chinese-funded grows in fentanyl trafficking and human rights violations. This angle, already gaining traction with federal agencies and law enforcement, could help justify reform from a conservative perspective.

The second half of the episode featured John Kueber, CEO of Nevis Brands, who discussed consumer trends in the cannabis beverage sector. He reported that hemp-derived THC beverages are now accounting for up to 50% of alcohol sales in some North and South Carolina stores. Kueber argued that hemp beverages are likely to outpace cannabis-based drinks due to broader retail access and stronger distribution networks. He forecasted the U.S. hemp beverage market could grow from $500 million to $2 billion in the next four years.

The episode concluded with updates on expected legislation in Pennsylvania and Texas, noting June 23 as a critical date for cannabis policy decisions that could significantly impact both state and national markets.


You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More